Page 96 - Sitomegalovirüs Tanı, Tedavi Uzlaşı Raporu

33. Hayden RT, Yan X, Wick MT, et al. Factors contrubuting to variability of quantitative
viral PCR results in proficiency testing samples: a multivariate analysis. J Clin
Microbiol. 2012;50:337-345.
34. Pang XL, Fox JD, Fenton JM, et al. Interlaboratory comparison of CMV viral load
assays. Am J Transplant. 2009;9:258-268.
35. Hirsch HH, Lautenschlager I, Pinsky BA, et al. An international multicenter
performance analysis of cytomegalovirus load tests. Clin Infect Dis. 2013;56:367-373.
36. Lilleri D, Lazzarotto T, Ghisetti V, et al. Multicenter quality control study for human
cytomegalovirus DNAemia quantification. New Microbiol. 2009;32:245-253.
37. Abbate I, Piralla A, Calvario A, et al. Nation-wide measure of variability in HCMV,
EBV and BKV DNA quantification among centers involved in monitoring transplanted
patients. J Clin Virol. 2016;82:76-83.
38. Kır O, Zeytinoğlu A, Arda B, Yılmaz M, Aşçı G, Töz H. Impact of Prophylaxis vs Pre-
emptive Approach for Cytomegalovirus Infection in Kidney Transplant Recipients.
Transplant Proc. 2017;49(3):537-540.
39. Caskurlu H, Karadag FY, Arslan F, Cag Y, Vahaboglu H. Comparison of universal
prophylaxis and preemptive approach for cytomegalovirus associated outcome
measures in renal transplant patients: A meta‐analysis of available data. Transpl
Infect Dis. 2019;21(1):e13016.
40. Lowance D, Neumayer HH, Legendre CM, et al. Valacyclovir for the prevention of
CMV disease after renal transplantation. International Valacyclovir CMV Prophylaxis
Transplantation Study Group. N Eng J Med. 1999;340(19):1462-1470.
41. Reischig T, Kacer M, Jindra P, et al. Randomized trial of valganciclovir versus
valacyclovir prophylaxis for prevention of CMV in renal transplantation. Clin J Am Soc
Nephrol. 2015;10(2):294-304.
42. Xin W, Hui Y, Xiaodong Z, et al. Effectiveness of Valganciclovir 900mg versus 450
mg for Cytomegalovirus Prophylaxis in Renal Transplantation: A Systematic Review
and Meta-Analysis. J Pharm Pharm Sci. 2017;20:168-183.
43. Chamberlain CE, Penzak SR, Alfaro RM, et al. Pharmacokinetics of low and
maintenance dose valganciclovir in kidney transplant recipients. Am J Transplant.
2008;8:1297-1302.
44. Martin-Gandul C, Perez-Romero P, Sanchez M, et al. Determination, validation and
standardization of a CMV DNA cut-off value in plasma for preemptive treatment of
CMV infection in solid organ transplant recipients at lower risk for CMV infection. J
Clin Virol. 2013;56:13-18.
45. Asberg A, Humar A, Jardine AG, et al. Long-term outcomes of CMV disease
treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients.
Am J Transplant. 2009;9:1205-1213.
46. Asberg A, Jardine AG, Bignamini AA, et al. Effects of the intensitiy of
immunosupressive therapy on outcome of treatment for CMV disease in organ
transplant recipients. Am J Transplant. 2010;10:1881-1888.
47. Eid AJ, Arthurs SK, Deziel PJ, et al. Clinical predictors of relapse after treatment of
primary gastrointestinal CMV disease in solid organ transplant recipients. Am J
Transplant. 2010;10:157-161.
48. Humar A. What's new and hot in clinical organ transplantation: report from American
Transplant Congress 2012. Am J Transplant 2013;13(2):281-285.
49. Razonable RR, Humar A. Cytomegalovirus in solid organ transplantation. Am J

93